INTRODUCTION {#sec1-1}
============

Lipids have always been held responsible for pathogenesis of cardiovascular diseases. Researchers have recently discovered the association of circulating lipids with diseases including breast cancer.[@ref1] In Pakistan incidence of occurrence is 2--5 times higher than other countries and one out of nine females suffer from this disease.[@ref2] Breast cancer occurrence related hyperlipidemia was related with short breast feeding period, family breast cancer history due to mutation in BRCA1 and BRCA2.[@ref3] Obesity with high BMI was related with ER positive breast cancer irrespective of menopausal status.[@ref4] Infiltrating ductal carcinoma is an invasive type of breast cancer arising from the duct and infiltrate into the surrounding tissues.[@ref5] Cancer stages are I-III and IV, stages I-III define cancer spread with increase in tumor size and lymph node involvement whereas stage IV is related with cancer spread to other parts of the body.[@ref6] Tumor Grade has specific significance in cancer biology, high Tumor Grade was associated with micro calcification, necrosis and fibrosis.[@ref7] One of the main prognostic factors that determine cancer prognosis is tumor size. Large tumor size is associated with lymph node metastasis.[@ref8] It was reported that breast cancer occurrence in women initiate a number of biochemical changes. Peripheral tissues provide free fatty acids to enhance tumor growth.[@ref9] Less glucose consumption was reported by nonmetastatic cells as compared to metastatic cells, therefore metastatic cells consume more glucose and express high glycolysis.[@ref10]

The aim of the study was to evaluate the hyperglycemia and hyperlipidemia including total cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol in breast Cancer Patients at initial diagnosis and to correlate the estimated changes with Tumor histopathology.

This study will create awareness in females to safe themselves from this deadly disease by controlling their blood sugar levels and lipid profile through changes in dietary habits and life style.

METHODS {#sec1-2}
=======

The study was conducted at Liaquat National Hospital Karachi on 208 non-pregnant female breast cancer patients of 30-60 years age, having children with breast feeding period less than six months. Females with past disease history other than cancer or on any medication were excluded from the study. Patients selected had primary infiltrating ductal carcinoma in one breast only. Disease stage I-III was included and stage IV patients (cancer metastasis to other organs) were excluded from the study on the basis of bone scan and ultra sound. Life history and social status of 176 healthy control subjects was matched with that of breast cancer patients.

The tumor Histopathology considered for the study was Tumor Grade-I to III, Tumor sizes \< 2 cms, 2-5 cm and \> 5 cm. Patients were classified on the basis of Axillary lymph node (ALN) metastasis. Seventy six Patients were without lymph Node metastasis and 148 patients with ALN metastasis. Cancer staging was according to the TNM system, stage IA (invasive tumor \< 20 mm. ALN without tumor), Stage IB (tumor \< 20 mm. metastasis in ALN 0.2- 2mm, prognostic group(PG)- 2), stage IIA tumor 20-50mm ALN metastasis free, PG- 3), IIB (tumor 20-50mm 1-3 ALN metastasis prognostic group 1/ tumor \> 50mm no tumor in ALN. PG 2), stage IIIA (Invasive tumor \> 50mm, cancer in 4-9 ALN, PG 4).[@ref11]

Blood samples were collected at the time of disease diagnosis, without any treatment. Tissue histopathology was performed according to method of Harris\'s Haematoxylin and Eosin staining method.[@ref12] Nottingham Modification of the Bloom-Richardson system was used for microscopic grading of breast carcinoma.[@ref13] The biochemical estimations were done by Kit provided by Roche Diagnostics GmbH, D-68298 Mannheim, Germany. Chemistry analyzer Hitachi 912 used for analysis was provided by Roche diagnostic Basil Germany. Schmidt and Peterson and Young method was used for estimation of glucose, as a reference.[@ref14] Estimation of Cholesterol method was based on Tinder reaction,[@ref15] HDL was estimated by polyethylene glycol modified enzymes and dextran sulfate.[@ref16] LDL was estimated by modified method of Friedewald 1972.[@ref17] Triglycerides were detected by Wahlefeld\'s method modified in 1990.[@ref18]

All experimental data was expressed as mean ± SEM. Data was analyzed by one way ANOVA using SPSS version (version 19.0). p\< 0.05 was considered as significant.

RESULTS {#sec1-3}
=======

In all breast cancer patients (208) blood random glucose level, total cholesterol (TC), triglyceride (TG) and low density lipoprotein (LDL) were significantly high and high density lipoprotein (HDL) was found significantly low as compared to control subjects, \*p\<0.05. Level of blood random glucose and lipid profile was significantly high in patients with lymph node metastasis as compared to that without lymph node metastasis ^▲^p\<0.05 ([Table-I](#T1){ref-type="table"}).

###### 

Blood random glucose level and lipid profile in breast cancer patients.

  Blood random glucose and lipid profile level (mg/dL)   Patients with lymph node metastasis                                              Patients without lymph node metastasis          Control Subjects
  ------------------------------------------------------ -------------------------------------------------------------------------------- ----------------------------------------------- ------------------
  Blood Glucose                                          135.0 ± 0.27 [\*](#t1f1){ref-type="table-fn"}^[▲](#t1f2){ref-type="table-fn"}^   132.1 ± 0.45 [\*](#t1f1){ref-type="table-fn"}   129.7 ± 0.22
  Cholesterol                                            190.9 ± 0.56 [\*](#t1f1){ref-type="table-fn"}^[▲](#t1f2){ref-type="table-fn"}^   183.3 ± 0.80                                    180.9 ± 0.57
  Triglyceride                                           134.0 ± 0.66 [\*](#t1f1){ref-type="table-fn"}^[▲](#t1f2){ref-type="table-fn"}^   118.1 ± 1.04 [\*](#t1f1){ref-type="table-fn"}   105.7 ± 0.41
  LDL                                                    118.9 ± 0.64 [\*](#t1f1){ref-type="table-fn"}^[▲](#t1f2){ref-type="table-fn"}^   103.0 ± 1.23 [\*](#t1f1){ref-type="table-fn"}   89.5 ± 0.28
  HDL                                                    40.0 ± 0.27 [\*](#t1f1){ref-type="table-fn"}^[▲](#t1f2){ref-type="table-fn"}^    52.3 ± 0.88 [\*](#t1f1){ref-type="table-fn"}    54.0 ± 0.23

p\<0.05, compared with the normal control group.

p\<0.05 in patients with lymph node metastasis compared with those without lymph node metastasis.

Patients were grouped on the basis of tumor histopathology including tumor grade, tumor size and ALN metastasis status. Tumor Grade-I patients were 32 out of these 62.5 % (20) patients were without ALN metastasis. 105 patients were with tumor Grade-II, out of these 26.7% (28) were without ALN metastasis. Patients with tumor Grade-III were 71 out of these 16.9% (12) were without ALN metastasis, percentage of patients without axillary lymph node (ALN) metastasis decreased with the increase in tumor grade. Patients with ALN metastasis in all tumor grades had significantly high Blood random glucose level, TC, TG and LDL whereas HDL was found significantly low as compared to the patients without ALN metastasis, \*p\<0.05. In patient with ALN metastasis and tumor Grade-II (77), 4% increase in total cholesterol, 23% increase LDLcholesterol and 11% increase in triglycerides were observed as compared to 12 tumor Grade-I patients. Among patients without ALN metastasis increase in Lipid profile percentage was less in 28 tumor Grade-II patients as compared to 20 Grade-I patients, total cholesterol and triglyceride increased 2% and LDL-cholesterol 20%. Percentage variation in glucose level was not observed on increase in tumor grade. As tumor Grade-Increased from II to Grade-III 1.7% increase in TC of 59 patients was observed whereas in 12 patients without ALN metastasis increase in cholesterol was 1.5% and TG 10.9% ([Table-II](#T2){ref-type="table"}).

###### 

Effect of tumor grade on blood glucose level and lipid profile in breast cancer patients.

  Blood random glucose and lipid profile level (mg/dL)   Tumor Grade-I                                  Tumor Grade-II   Tumor Grade 3                                                                                               
  ------------------------------------------------------ ---------------------------------------------- ---------------- --------------------------------------------- -------------- ---------------------------------------------- --------------
  Blood Random Glucose                                   134.7± 0.99[\*](#t2f1){ref-type="table-fn"}    130.1± 0.42      134.7± 0.37[\*](#t2f1){ref-type="table-fn"}   132.7± 0.71    135.5 ± 3.33                                   134.0± 0.98
  Cholesterol                                            184.1 ± 0.89[\*](#t2f1){ref-type="table-fn"}   180.4± 0.15      191.6± 0.69[\*](#t2f1){ref-type="table-fn"}   183.8 ± 1.28   191.4 ± 0.96[\*](#t2f1){ref-type="table-fn"}   186.7 ± 2.05
  HDL                                                    41.3 ± 0.83[\*](#t2f1){ref-type="table-fn"}    53.6 ± 0.64      39.4 ± 0.36[\*](#t2f1){ref-type="table-fn"}   52.0 ± 1.78    38.3 ± 0.35[\*](#t2f1){ref-type="table-fn"}    50.7± 0.88
  LDL                                                    97.3± 0.96[\*](#t2f1){ref-type="table-fn"}     91.9± 0.91       120.6 ±0.44[\*](#t2f1){ref-type="table-fn"}   110.3 ± 1.15   121.1 ± 0.64[\*](#t2f1){ref-type="table-fn"}   104.1 ± 0.83
  Triglycerides                                          120.2 ± 1.76[\*](#t2f1){ref-type="table-fn"}   114.2± 1.31      134.2± 0.71[\*](#t2f1){ref-type="table-fn"}   116.2 ± 1.32   136.5 ± 0.99[\*](#t2f1){ref-type="table-fn"}   128.9± 0.98

p\<0.05 as compared with the patients without lymph node metastasis

Effect of disease stage based on tumor size and ALN on random blood glucose level and lipid profile was evaluated in breast cancer patients. Total 16 patients were studied with tumor size \< 2cm, out of these 13 patients were without ALN metastasis (81%) at cancer stage IA and 03 patients with ALN metastasis (19%) were at cancer stage IB. No comparative significant change was found in blood random glucose, total cholesterol and LDL levels. High density lipoproteins were significantly low and triglycerides were significantly high in patients with metastasis as compared to that without metastasis. Patient group of 76 was studied with tumor size 2-5 cm, 27 patients (35.5%) were without ALN metastasis, at cancer stage IIA and 49 (64.4%) with ALN metastasis at cancer stage IIB. Patients at cancer stage IIB had significantly high blood sugar, TC, HDL, LDL levels and significantly low HDL levels as compared to the patients at cancer stage IIA. Total 116 Patients with tumor size \> 5cm were studied, 96 patients (80.2%) with ALN metastasis at cancer stage IIIA and 20 patients (17.2%) without ALN metastasis at cancer stage IIB. Patients with cancer stage IIIA had significantly high blood random glucose level, TC, TG and LDL whereas significantly low HDL as compared to the patients at cancer stage IIB \*p\<0.05. Results suggest that biochemical variations are increased with the disease advancement accompanied by tumor size increase from \<2 to 2,5cm. and ALN metastasis. Blood random glucose level (4%), TC (1.7%), TG (2%) and LDL (3%) increased whereas HDL significantly decreased (2%), these variations remain unchanged on further increase in tumor size (2.5- 5cm). In patients without ALN metastasis biochemical variations with the increase in tumor size were less, increase was found only in TC (2%), LDL-cholesterol (6.5%) and TG (5.2%) ([Table-III](#T3){ref-type="table"}).

###### 

Effect of Cancer stage on blood glucose level and lipid profile in breast cancer patients.([@ref11])

                         Tumor size \< 2cm   Tumor size (2-5)cm                           Tumor size \> 5cm                                                              
  ---------------------- ------------------- -------------------------------------------- ------------------- --------------------------------------------- ------------ --------------------------------------------
  Blood random Glucose   131.7± 0.88         129.7±0.88                                   131.8± 0.68         135.4± 0.42[\*](#t3f1){ref-type="table-fn"}   132.7±0.81   135.0±0.34[\*](#t3f1){ref-type="table-fn"}
  Cholesterol            179.8± 0.82         187.7± 4.98                                  183.3± 1.14         190.9± 1.05[\*](#t3f1){ref-type="table-fn"}   185.5±1.64   191.0±0.66[\*](#t3f1){ref-type="table-fn"}
  HDL                    51.8±1.10           40.9±1.53[\*](#t3f1){ref-type="table-fn"}    51.9 ± 1.51         40.0± 0.41[\*](#t3f1){ref-type="table-fn"}    53.3 ±1.55   39.5±0.34[\*](#t3f1){ref-type="table-fn"}
  LDL                    97.5± 2.73          111.0±6.12                                   103.9± 2.05         114.6± 1.48[\*](#t3f1){ref-type="table-fn"}   105.3±1.42   121.4±0.43[\*](#t3f1){ref-type="table-fn"}
  Triglycerides          113.0±1.64          133.7±3.85[\*](#t3f1){ref-type="table-fn"}   118.9± 1.61         132.2± 1.47[\*](#t3f1){ref-type="table-fn"}   120.4±1.73   135.0±0.66[\*](#t3f1){ref-type="table-fn"}

p\<0.05 as compared with the patients without lymph node metastasis.

Disease free survival (DFS) was the period between treatment completion and reappearance of first disease symptom and it was calculated in months. About 18.75% (39) patients had DFS \< 24 months, out of these 79.5% (31) were patients with ALN metastasis. 74% (154) patients had DFS of 24-48 months, patients with lymph node metastasis were 71% (110). 72% (15) patients had DFS of \> 48 month and 46% (07) were with ALN metastasis. ALN metastasis is associated with cancer stage IB, IIB and IIIA, study indicates low percentage of patient with progressed disease is associated with high DFS. In patients with ALN metastasis blood random glucose level, total cholesterol, LDL and triglyceride were significantly high and HDL was significantly low in patients as compared to the patients without ALN metastasis\*p\<0.05 ([Table-IV](#T4){ref-type="table"}). No relation of biochemical variation was developed with DFS.

###### 

Effect of blood random glucose level and lipid profile on disease free survival in breast cancer patients.

                         Months\< 24                                    Months 24-47   Months\>48                                                                                                   
  ---------------------- ---------------------------------------------- -------------- ---------------------------------------------- -------------- ---------------------------------------------- --------------
  Blood random Glucose   135.4 ± 0.61[\*](#t4f1){ref-type="table-fn"}   132.1 ± 1.18   134.9± 0.31[\*](#t4f1){ref-type="table-fn"}    132.2 ± 0.53   134.7 ± 0.94[\*](#t4f1){ref-type="table-fn"}   131.4 ± 1.30
  Cholesterol            190.2 ± 1.15[\*](#t4f1){ref-type="table-fn"}   183.1 ± 2.93   190.9 ± 0.66[\*](#t4f1){ref-type="table-fn"}   183.4 ± 0.93   193.8 ± 2.11[\*](#t4f1){ref-type="table-fn"}   182.9 ± 2.06
  HDL                    40.3 ± 0.36[\*](#t4f1){ref-type="table-fn"}    49.4 ± 1.67    39.9 ± 0.34[\*](#t4f1){ref-type="table-fn"}    53.0 ± 1.10    40.1 ± 0.42[\*](#t4f1){ref-type="table-fn"}    51.4 ± 1.86
  LDL                    119.7 ± 0.81[\*](#t4f1){ref-type="table-fn"}   103.2 ± 3.73   118.4 ± 0.82[\*](#t4f1){ref-type="table-fn"}   102.2 ± 1.36   122.4 ± 0.99[\*](#t4f1){ref-type="table-fn"}   106.9 ± 3.82
  Triglycerides          135.2 ± 1.68[\*](#t4f1){ref-type="table-fn"}   113.0 ± 2.09   133.7 ± 0.74[\*](#t4f1){ref-type="table-fn"}   119.2 ± 1.24   132.8 ± 1.03[\*](#t4f1){ref-type="table-fn"}   115.4± 2.73

p\<0.05 as compared with the patients without lymph node metastasis.

DISCUSSION {#sec1-4}
==========

In the breast cancer patients, significant variations were observed in random blood glucose, and lipid profile as compared to control subjects, \*p\<0.05 their role in disease occurrence may be predicted. Hyperlipidemia and hyperglycemia were comparatively more significant in patients with lymph node metastasis. Lymph node status indicates the ability of tumor to spread.[@ref6] It was suggested by the studies that increased plasma cholesterol level plays a role in breast cancer occurrence and progress.[@ref19]

The study was further extended to evaluate the relation between biochemical changes and disease stage based on histopathology, including tumor grade, tumor size and lymph node metastasis. Past Studies have correlated high tumor grade with lymph node metastasis.[@ref20] Patients with lymph node metastasis in all tumor grades had significantly high blood random glucose level and hyperlipidemia percentage as compared to patients without metastasis, indicating tumor grade along with lymph node metastasis was responsible for increasing lipid profile. Present study indicated significant blood glucose and lipid profile increase in patients with lymph node metastasis at disease stage (IB, IIB, IIIA) as compared to that without lymph node metastasis with increase in tumor size (IA, IIA). The cancer mass present in the lymph nodes increased the total cancer mass from which the spread can take place. Cancer spread can be explained by the process including (size + node equation).[@ref21] Percentage variation in blood glucose and lipid profile were high in patients up to tumor size 2.5cm, variations were less if the tumor size increased beyond 5cm. Therefore, study correlates the biochemical variations with tumor activity at early stage. Alterations in lipid profile levels have been significantly related with disease stage.[@ref22]

Disease free survival (DFS) of the patients were correlated with biochemical variations. Hyperlipidemia and hyperglycemia were more significant in patients with lymph node metastasis as compared to patients without lymph node metastasis. About 79% patients with lymph node metastasis had DFS less than 24 months, 71.4% patients had DFS OF 24-48 months and 46% metastatic patients had DFS of greater than 48 months. No relation between hyperlipidemia and DFS was developed. Mortality risk by breast cancer was related with lymph node metastasis earlier.[@ref23] Hyperglycemia in breast cancer patients has been linked with insulin resistance. Insulin exerts various metabolic effects and also works in the proliferation of cells. Tumor growth can be enhanced by hyperglycemia since DNA synthesis of tumor cells is increased by hyperglycemia.[@ref24]

Breast cancer occurrence is related with estrogen and estrogen increased the growth hormone release which in turn induces a state of insulin resistance.[@ref25] Alterations in lipid profile related to histopathology may be attributed to the metabolic changes produced by tumor activity.

Risk of breast cancer reoccurrence has been correlated with, overall hyperlipidemia including high serum cholesterol, LDL-cholesterol and triglycerides.[@ref26] According to the past study low level of HDL and high level of LDL-cholesterol promotes metastasis & proliferation.[@ref27] The increased level of triglycerides may be attributed to the decreased hepatic triglyceride lipase activity.[@ref28]

Strength and Limitations {#sec2-1}
------------------------

Study indicates that tumor with poor histopathology including lymph node metastasis, high tumor grade and large tumor size had significant biochemical variations and low disease free survival. Limitation was that samples were collected from one center only.

CONCLUSION {#sec1-5}
==========

Study related hyperlipidemia and hyperglycemia with disease stage and was significant in patients with progressed disease IB, IIB and IIIA. No independent relation of disease free survival was developed with hyperlipidemia and hyper glycemia. Disease free survival was dependent on tumor histopathology.

Implications {#sec2-2}
------------

Study can guide the oncologist to predict the disease prognosis on the basis of pretreatment biochemical profile.
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